Open Access Case Report

New Paradigms in the Treatment of Metastatic Hepatocarcinoma: Case Report

Everton GA Melo1*, Gleidson M Silva2 and Alan F Soares3

1Department of Clinical Oncology, Londrina Cancer Hospital, Brazil

2Department of Radiology, Ultramed Londrina, Brazil

3Department of Clinical Oncology, Londrina Cancer Hospital, Brazil

Corresponding Author

Received Date: May 19, 2021;  Published Date: June 09, 2021


In the past 12 years, multiquinase inhibitors, sorafenib and lenvatinib, represented the main first-line systemic treatments of hepato- carcinoma not amenable to local or metastatic treatment. The results of the phase III study, IMbrave 150, which compared atezolizumab plus bevacizumab versus sorafenib, represented an important advance in the first-line treatment. We report a clinical case of a 78-year-old patient with metastatic hepatocarcinoma, who underwent first-line treatment with the combination of atezolizumab and bevacizumab. After 3 treatment cycles, there was a complete response in the lung and a partial response in the liver, opening the discussion about the possibility of considering at some point the local treatment of the liver in the face of tumor downstaging.

Keywords: Hepatocarcinoma; Immunotherapy; Downstaging

Signup for Newsletter
Scroll to Top